Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Blood (2023) 142 (Supplement 1): 961.

https://doi.org/10.1182/blood-2023-190495

Published: 2023

Journal Articles

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Vilmarie Rodriguez, Meenakshi Devidas, Zhiguo (Bruce) Chen, Andrew J Carroll, Nyla A. Heerema, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Naomi J Winick, Elizabeth A. Raetz, Mignon L. Loh, Michael J. Burke, Wanda L. Salzer, Stephen P. Hunger, Karen R. Rabin

Blood (2023) 142 (Supplement 1): 824.

https://doi.org/10.1182/blood-2023-185368

Published: 2023

Journal Articles

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Nathan P. Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey

Blood (2023) 141 (15): 1802–1811.

https://doi.org/10.1182/blood.2022018653

Published: 2023

Includes: Supplemental data

Journal Articles

The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children's Oncology Group Study

Sarah Alexander, Sumit Gupta, John Kairalla, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J Winick, Kevin R. Krull, Wanda L Salzer, Michael J. Burke, Lia Gore, Meenakshi Devidas, Stephen P. Hunger, Mignon L. Loh, Kristina Hardy

Blood (2022) 140 (Supplement 1): 2179–2180.

https://doi.org/10.1182/blood-2022-166765

Published: 2022

Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, David S. Ziegler, Francisco Bautista, Andishe Attarbaschi, Lia Gore, Franco Locatelli, Maureen M. O'Brien, Melinda Pauly, Mihaela Obreja, Christopher L. Morris, Andre Baruchel

Blood (2021) 138 (Supplement 1): 1235.

https://doi.org/10.1182/blood-2021-147588

Published: 2021

Journal Articles

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

David S. Ziegler, Van Huynh, Michael J. Burke, Lia Gore, Franco Locatelli, Maureen M. O'Brien, Christopher Kim, Mihaela Obreja, Christopher L. Morris, André Baruchel

Blood (2021) 138 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2021-153865

Published: 2021

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Blood (2021) 138 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2021-149365

Published: 2021

Journal Articles

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Blood (2021) 138 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2021-148593

Published: 2021

Journal Articles

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Blood (2021) 138 (Supplement 1): 211.

https://doi.org/10.1182/blood-2021-147386

Published: 2021

Journal Articles

Novel Germline TRAF3IP3 Mutation in a Dyad with Familial Acute B Lymphoblastic Leukemia

Lauren Pommert, MDMS, Robert Burns, MD, Quinlan Furumo, Kirthi Pulakanti, Jon Brandt, Michael J Burke, MD, Sridhar Rao, MDPhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-137198

Published: 2020

Journal Articles

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139081

Published: 2020

Journal Articles

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-143165

Published: 2020

Journal Articles

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134327

Published: 2020

Journal Articles

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232

Michael J. Burke, MD, Meenakshi Devidas, PhD, Zhiguo Chen, MS, Wanda Salzer, MD, Elizabeth A. Raetz, MD, Karen R. Rabin, MD PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Julie M. Gastier Foster, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, Naomi Winick, MD, William Carroll, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Eric Larsen, MD

Blood (2019) 134 (Supplement_1): 286.

https://doi.org/10.1182/blood-2019-127052

Published: 2019

Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, MD, David S. Ziegler, MBBS, FRACP, MD, Francisco José Bautista Sirvent, MD PhD, Andishe Attarbaschi, MD, Lia Gore, MD, Franco Locatelli, MD PhD, Maureen M O'Brien, MD, Melinda Pauly, MD, Mihaela Obreja, PhD, Christopher L. Morris, PhDMD, Andre Baruchel, MD

Blood (2019) 134 (Supplement_1): 3873.

https://doi.org/10.1182/blood-2019-127350

Published: 2019

Journal Articles

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Kathryn G. Roberts, PhD, Samuel W. Brady, PhD, Zhaohui Gu, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Deqing Pei, MS, Cheng Cheng, PhD, Yunfeng Dai, PhD, Meenakshi Devidas, PhD, Chunxu Qu, PhD, Ashley Hill, BS, Xiaotu Ma, Lei Wei, PhD, Sasi Arunachalam, PhD, Kohei Hagiwara, MD, Yangling Liu, Diane Flasch, Yu Liu, PhD, Matthew Parker, PhD, Xiaolong Chen, PhD, Yongjin Li, PhD, Yiping Fan, PhD, Robert Michael, PhD, Michael Rusch, BS, Mark Wilkinson, Scott Foy, PhD, Dale Hedges, PhD, Scott Newman, PhD, Xin Zhou, PhD, Jian Wang, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Patee Gesuwan, Malcolm A Smith, MD PhD, Daniela S. Gerhard, PhD, Naomi Winick, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Eric Larsen, MD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent L Wood, MD PhD, William L. Carroll, MD, Patrick A. Zweidler-McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly Maloney, MD, Stuart S. Winter, MD, Michael J. Burke, MD, Wanda L. Salzer, MD, Kimberly P. Dunsmore, Anne Angiolillo, MD, Kristine R Crews, PharmD, James R. Downing, MD, Sima Jeha, MD, William E. Evans, PharmD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Mary V. Relling, PharmD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Jinghui Zhang, PhD, Charles G. Mullighan, MBBS, MD

Blood (2019) 134 (Supplement_1): 649.

https://doi.org/10.1182/blood-2019-124881

Published: 2019

Journal Articles

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Lauren Pommert, MDMS, Deepa Bhojwani, MD, Richard Sposto, PhD, Ellynore Florendo, Eric Schafer, MD, Nathan Gossai, MD, Van Thu Huynh, MD, Sridhar Rao, MD PhD, Michael J. Burke, MD

Blood (2019) 134 (Supplement_1): 1325.

https://doi.org/10.1182/blood-2019-127298

Published: 2019

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets

Rumen Kostadinov, PhD, Byunggil Yoo, MS, Midhat S. Farooqi, MD PhD, Shannon Kelley, MS, Erin Guest, MD, Michael J. Burke, MD, Sarah Wheelan, MD PhD, Patrick Brown, MD

Blood (2018) 132 (Supplement 1): 918.

https://doi.org/10.1182/blood-2018-99-119206

Published: 2018

Journal Articles

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Andrew E. Place, MD PhD, Traci M. Blonquist, MS, Elliot Stieglitz, MD, Todd M Cooper, DO, Lia Gore, MD, Richard Aplenc, MD PhD, Mignon L. Loh, MD, Melinda Pauly, MD, Rachel E. Rau, MD, Michael J. Burke, MD, Julia Etchin, PhD, A. Thomas Look, MD, Maria Luisa Sulis, MD, Lewis B. Silverman, MD

Blood (2018) 132 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2018-99-116689

Published: 2018

NARROW

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children's Oncology Group Study

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Novel Germline TRAF3IP3 Mutation in a Dyad with Familial Acute B Lymphoblastic Leukemia

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only